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Abstract 
Objective: To investigate differences in distribution of α4β2 subtypes of nicotinic 
acetylcholine receptors (nAChRs) using the ligand 123I-5-Iodo-3-[2(S)-2-
azetidinylmethoxy] pyridine (5IA-85380) and single photon emission computed 
tomography (SPECT) in subjects with vascular dementia and age-matched controls. 123I-
5IA-85380 binding was compared to corresponding regional cerebral blood flow (rCBF) 
changes in the same subjects. 
Methods: Thirty subjects (14 vascular dementia and 16 controls) underwent 123I-5IA-
85380 and rCBF (99mTc-exametazime) SPECT scanning. Image analysis was performed 
on voxel basis using statistical parametric mapping (SPM2).  
Results: Compared to controls, reductions in relative 123I-5IA-85380 uptake were 
identified in dorsal thalamus and right caudate in vascular dementia. Increase in scaled 
123I-5IA-85380 uptake in cuneus was also demonstrated in vascular dementia relative to 
controls. Perfusion deficits in anterior cingulate were apparent in the patient group and 
did not appear to be associated with 123I-5IA-85380 changes. 
Conclusions: Reduced 123I-5IA-85380 uptake in vascular dementia was confined to sub-
cortical regions, unlike the cortical reductions previously described in Alzheimer’s 
disease. Elevation of normalised 123I-5IA-85380 uptake in cuneus in vascular dementia 
could be a compensatory response to reduced cholinergic activity in dorsal thalamus.  
 
Keywords: SPECT; Nicotinic; Vascular dementia; SPM 
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1. Introduction  
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels whose 
action is controlled by acetylcholine (ACh) and nicotinic agonists. They are distributed 
throughout the human brain and are involved in a range of physiological processes 
including cognitive and sensory function, memory, learning, arousal, reward and motor 
control (Jones et al., 1999). The most abundant varieties of nAChRs in humans are the 
α4β2 and α7 subtypes (Le Novere and Changeux, 1995; Lindstrom et al., 1995). 
Reduction of these and other nicotinic receptor subtypes has been observed in vitro in 
Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) and Parkinson’s disease 
(PD) (Court et al., 2000; Perry et al., 1994; Pimlott et al., 2004; Rinne et al., 1991; Sihver 
et al., 1999). 
 
Vascular dementia (VaD), along with AD and DLB, is one of the commonest causes of 
dementia in older people. VaD is increasingly viewed as part of a broader spectrum of 
vascular cognitive impairment (O'Brien et al., 2003), and classification is largely based 
on the most prominent site of vascular pathology, for example multi-infarct (cortical), 
subcortical ischaemic and strategic-infarct (O'Brien et al., 2003). Clinical features of VaD 
are diverse and depend largely upon location of the vascular pathology, but impairments 
in attention and executive function, with slowing of motor performance and information 
processing are frequently seen, especially in those with subcortical VaD (O'Brien et al., 
2003). In contrast, episodic memory is relatively spared, unlike AD (Babikian and 
Ropper, 1987). 
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The extent of cholinergic involvement in VaD remains controversial. Some have reported 
cholinergic loss (Gottfries et al., 1994; Tomimoto et al., 2005), while others found 
cholinergic changes only in mixed, not “pure” VaD (Perry et al., 2005). Similarly, while 
cholinergic replacement therapy is effective in AD and mixed dementia (Erkinjuntti et al., 
2002), results from studies in VaD have generally been disappointing (Roman et al., 
2005; Wilkinson et al., 2003). Few studies, all limited to autopsy, have investigated the 
distribution of nAChRs in VaD. Using 3H-epibatidine, a ligand for the α4 nicotinic 
receptor, Martin-Ruiz et al observed significant reductions in binding in temporal cortex 
in VaD compared to age-matched controls. However, results were confounded by 
subjects having a history of tobacco smoking and when smoking histories were taken into 
account; α4 nAChRs did not differ amongst groups (Martin-Ruiz et al., 2000). More 
recently, the marker 125I-5-Iodo-3-[2(S)-2-azetidinylmethoxy] pyridine (5IA-85380), a 
high affinity nAChR ligand that demonstrates high selectivity for the α4β2 nAChRs, has 
also been investigated. In autopsy studies, receptor binding in VaD was found to be 
indistinguishable from age-matched controls in entorhinal cortex, insula, recticular 
nucleus, striatum, subthalamic nucleus, substantia nigra and various thalamic nuclei 
(Pimlott et al., 2004), in contrast to reductions in most of these regions in AD. 
 
Neuropathological studies of nAChRs in dementia provide important information but are 
limited as they are restricted to end stage disease and have to be focussed on specific 
brain areas. Molecular in vivo imaging has been shown to have a role in assessing various 
subunits of nAChRs in vivo in AD and DLB (Kadir et al., 2006; Nordberg et al., 1995; 
O'Brien et al., 2007, 2008). Presently, no imaging studies have investigated nAChRs in 
  5
antemortem VaD. Regional cerebral blood flow (rCBF) and metabolic patterns have been 
assessed in VaD of the sub-cortical type using functional single photon emission 
computed tomography (SPECT) and positron emission tomography (PET) imaging with 
FDG. Such patterns are generally related to the nature and location of infarcts,  although 
hypoperfusion of anterior cingulate appears a consistent feature (Hanyu et al., 2004; Shim 
et al., 2006; Yang et al., 2002). Similarly, PET studies have revealed that metabolic 
reductions are predominantly in frontal lobe and anterior cingulate (Nagata et al., 2000; 
Sultzer et al., 1995), while others report more diffuse changes (Kerrouche et al., 2006).  
 
In the present study, we investigated differences in normalised 123I-5IA-85380 SPECT 
binding (an estimate of α4β2 nAChR status) in VaD relative to age-matched controls. In 
addition, we compared the difference in nicotinic pattern to the associated perfusion 
pattern obtained from 99mTc-exametazime SPECT scanning. In accordance with previous 
autopsy and rCBF SPECT evaluations, we hypothesised that in VaD (excluding sites of 
infarcts), relative 123I-5IA-85380 uptake is preserved in temporal and sub-cortical regions 
but rCBF would be reduced in anterior cingulate, frontal, temporal, and sub-cortical 
areas. Moreover, we assumed preservation of relative 123I-5IA-85380 uptake to extend to 
other cortical regions in VaD. 
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2. Methods 
2.1. Subjects 
The sample consisted of 14 VaD patients and 16 normal elderly control subjects (non-
smoking for more than 10 years). Patients were gathered from patients who had been 
referred to local community stroke and old age psychiatry services. Normal controls were 
recruited from friends and spouses of patients included in this and other research studies. 
All subjects underwent 123I-5IA-85380 and 99mTc-exametazime SPECT scanning. The 
study was approved by the local research ethics committee and UK Department of 
Health’s Administration of Radioactive Substances Advisory Committee (ARSAC). All 
participants, as well as the nearest relative for patients, gave informed written consent. 
 
2.2. Assessments and diagnosis 
Participants underwent physical, neurological and neuropsychiatric examinations, which 
included history, mental state and physical examination, and for VaD patients, a standard 
blood screen with thyroid function tests, B12, folate and syphilis serology and CT brain 
scan. Standardised assessments included the Mini-Mental State Examination (MMSE) 
(Folstein et al., 1975), the Cambridge Cognitive Examination (CAMCOG) (Roth et al., 
1986), the Neuropsychiatric Inventory (NPI) (Cummings et al., 1994) and fluctuation 
assessment scale (Walker et al., 2000). Diagnosis of VaD was made by consensus 
between two experienced researchers (J. T. O’Brien, S. Pakrasi) using the 
NINDS/ADRDA criteria for VaD (Roman, 2002). VaD patients were not receiving any 
cholinesterase medication. Controls had no evidence of cognitive disturbance, did not 
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complain of poor memory and all scored within normal range of cognitive tests (lowest 
CAMCOG score 91, lowest MMSE score 27).  
 
2.3. Radiochemistry 
The synthesis of 123I-5IA-85380 was carried out by the West of Scotland Radionuclide 
Dispensary, Glasgow University, as has been previously described (O'Brien et al., 2007). 
The dose was calibrated to the time of injection and transported to the department of 
nuclear medicine on the day before use. 
 
2.4. Image acquisition 
Subjects were imaged using a triple-headed rotating gamma camera (Picker 3000XP) 
fitted with a high resolution fan-beam collimator, approximately 2 hours after a bolus 
intravenous injection of 123I-5IA-85380. Scanning at 2 hours was chosen from time 
activity curve data and practical issues of imaging the patient group as previously 
described (O'Brien et al., 2007, 2008). This was the start of a period over which uptake 
ratio (regional uptake: whole brain uptake) in cortical regions remained relatively 
constant. Subsequently, one hundred and twenty 15 second views over a 360° orbit were 
acquired on a 128×128 matrix with a pixel and slice thickness of 3.5mm. Imaging time 
was 30 minutes. Images were reconstructed using ramp-filtered backprojection with a 
Butterworth filter (order 13, cut-off 0.3 cycles.cm-1), then resampled to a 64×64 matrix 
containing 4.0mm cubic voxels. The reconstructed images were then corrected for 
gamma ray attenuation using Chang’s method (µ = 0.11cm-1). Approximately one month 
after their 123I-5IA-85380 scan; all subjects, with the exception of one VaD patient, 
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underwent rCBF SPECT scanning 10 minutes after injection of 500 MBq of 99mTc-
exametazime (Ceretec, GE Healthcare, also referred to as HMPAO). Image processing 
and reconstruction was as above. All imaging data were then transferred to a PC for 
further analysis.  
 
2.5. Image analysis 
Imaging data for both radiotracers were initially converted from DICOM to Analyze 
formats using MRIcro (http://www.sph.sc.edu/comd/rorden/mricro.html). Spatial pre-
processing and statistical analysis of datasets were then performed using SPM2 
(http://www.fil.ion.ucl.ac.uk/spm) and MATLAB 7.1 running on a PC under Windows 
XP. First, all image volumes were required to be spatially normalised to match a 
perfusion 99mTc-exametazime SPECT template in standard MNI space (Montreal 
Neurological Institute, http://www2.bic.mni.mcgill.ca/). One possible drawback of using 
the MNI standard brain is that it was generated from much younger populations than 
those in the present study, but given the spatial resolution of the current dataset (~ 10 
mm); this was unlikely to affect the registrations. It was apparent from the scans that 10 
of the 14 VaD subjects had at least one significant cortical infarct/lesion. Such infarcts 
could lead to suboptimal spatial normalisation as the registration algorithm attempts to 
reduce image mismatch between the template and image at the site of the infarct. To 
avoid this, we masked the infarct during the normalisation, so that the infarct did not bias 
the transformations (Brett et al., 2001). Therefore, each subject underwent the following 
spatial pre-processing: 
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a) Within-mode coregistration between the 99mTc-exametazime and 123I-5IA-85380 
scans (target image = 99mTc-exametazime, object image = 123I-5IA-85380).  
 
b) Using MRIcro, a mask image of the infarct/lesion was produced from the 99mTc-
exametazime scan (if appropriate). 
 
c) Spatial normalisation (12-parameters affine) with function masking (if 
appropriate) of 99mTc-exametazime scan to SPECT template in standard MNI 
space.  
 
d) 3D transformation parameters calculated in (c) applied to the coregistered 123I-
5IA-85380 scan. 
 
e) Spatial smoothing of registered scans using 10mm FWHM 3D Gaussian filter.  
 
 
Fig. 1 illustrates an example of lesion masking for two VaD cases. Since registration 
accuracy was of a similar order to spatial resolution, image registration using purely 
linear transformations was considered satisfactory (Acton and Friston, 1998). The 
template image was generated from 39 elderly controls as previously described (O'Brien 
et al., 2007, 2008). Voxel size was preserved before and after spatial normalisation. All 
spatially normalised images were visually inspected to ensure accuracy of registrations.  
 
Once the images had undergone spatial pre-processing, the general linear model was 
employed to perform the appropriate voxelwise statistical tests (two sample t-test) in the 
assessment of group differences in relative 123I-5IA-85380 and 99mTc-exametazime 
uptake separately between VaD and controls. Correlations in VaD were investigated for 
each variable using linear regression with variables entered as covariates. Image intensity 
was normalised between subjects to prevent intersubject variability masking the regional 
changes. This was performed using proportional scaling (Frackowiak et al., 1997), where 
each image was scaled to its mean global brain activity (counts.voxel-1). Grey matter 
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threshold was set to 0.8, as this appeared effectively to exclude infarcts, extracerebral 
tissue and ventricles. Group effects and linear regression were assessed using a 
probability height threshold of P ≤ 0.001 uncorrected for multiple non-independent 
comparisons. Statistical inference was estimated from the distributional approximations 
from Gaussian random field theory (Friston et al., 1994). Regions were interpreted and 
reported as significant if their multiple-comparison corrected cluster-level significance 
was ≤ 0.05. 
 
2.6. Display of results 
Regions of significant difference in normalised 123I-5IA-85380 and 99mTc-exametazime 
scans were displayed as maximum intensity projections (glass brain) in three orthogonal 
planes. These maps were also displayed on selected planes of the 99mTc-exametazime 
SPECT template. All statistical maps were displayed for height thresholds of Puncorrected ≤ 
0.001, extent (k) ≥ 16 voxels (approx 1 cm3). Result localisation was performed by 
transformation from MNI to Talairach space (Brett, 1999), followed by input into the 
Talairach Daemon (http://www.talairach.org/daemon.html). 
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3. Results 
3.1. Subject characteristics 
Table 1 shows demographic and neuropsychological characteristics of controls and VaD. 
Groups were matched for age (F1, 28=1.6, p=0.2) and sex (χ2=0.3, df=1, p=0.6). As 
expected, VaD subjects performed worse on cognitive assessments than controls, i.e., 
MMSE (F1, 28=37.3, p<0.001), CAMCOG (F1, 28=30.5, p<0.001), CAMCOGmemory (F1, 
28=23.3, p<0.001) and executive function (F1, 28=40.8, p<0.001). In addition, according to 
NPI, 2 patients were depressed, 2 had hallucinations, and one had delusions. Of these 
subjects, 4 were receiving psychotropic medications. The two patients with depression 
were taking antidepressants. Of the two with hallucinations, one was taking an 
antipsychotic, the other an antipsychotic as well as anticonvulsant medication. 
 
3.2. Differences in 123I-5IA-85380 and 99mTc-exametazime binding between VaD and 
controls 
 
Fig. 2A shows the SPM map of decreased relative 123I-5IA-85380 uptake in VaD 
compared to controls. Reductions were apparent in sub-cortical structures such as dorsal 
thalamus, right caudate and white matter. Table 2A lists the location and peak statistical 
measures. In addition, a significant increase in normalised 123I-5IA-85380 uptake was 
observed in the cuneus bilaterally and in the right middle occipital gyrus in VaD relative 
to controls (fig. 2B), where table 2B details the location and peak statistical measures. 
Fig. 2C shows both results superimposed onto the 99mTc-exametazime SPECT template, 
illustrating the loss (blue region) and increase (orange region) of normalised 123I-5IA-
85380 uptake in VaD.  
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Changes in perfusion were investigated between VaD and controls. Marked deficits in 
rCBF were discovered in the anterior cingulate bilaterally in VaD compared to controls 
(fig. 3A and 3B). There were no regions where increases in 99mTc-exametazime binding 
were found in VaD relative to controls. Table 3 lists the location and peak statistical 
measures of the rCBF comparisons. Differences in rCBF and 123I-5IA-85380 between 
groups revealed distinct patterns. Fig. 4 shows representative 123I-5IA-85380 and 99mTc-
exametazime SPECT scans axially in MNI space of a control and VaD patient, where 
thalamic decline and cuneal increase in 123I-5IA-85380 binding was evident in VaD but 
not in the control, results which were quite different from perfusion changes.  
 
3.3. Association between thalamic and cuneal 123I-5IA-85380 uptake in VaD 
 
In an attempt to understand the apparent cuneal upregulation in VaD, and because of the 
known strong thalamo-occipital connections (including cholinergic) (Behrens et al., 
2003; Johansen-Berg et al., 2005), the relationship between thalamic and cuneal 123I-5IA-
85380 uptake in VaD was investigated. Normalised mean counts.voxel-1 for each 
significant cluster (figs. 2A and 2B) were extracted from scans using the SPM toolbox 
MarsBaR software (MARSeille Boîte À Région d'Intérêt) (Brett et al., 2002). The cluster 
data were then plotted (fig. 5), showing a negative trend (Pearson’s correlation coefficient 
r = -0.43, p=0.06) between thalamus and cuneal cluster binding in VaD. 
 
 
 
 
 
 
 
  13
3.4. Clinical and neuropsychological correlates of 123I-5IA-85380 and 99mTc-
exametazime uptake in VaD 
 
The relationship between image uptake and variables (sex, age, CAMCOG, 
CAMCOGmemory, executive function, fluctuation, NPI score) were investigated in VaD. 
No significant effects in any brain region were observed between these variables and 123I-
5IA-85380 and 99mTc-exametazime imaging data. 
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4. Discussion 
Using SPECT we investigated normalised 123I-5IA-85380 uptake, an estimate of α4β2 
nAChRs, in VaD compared to aged-matched controls. Decreased uptake in VaD was 
confined to sub-cortical areas, the dorsal thalamus, right caudate and white matter, while 
cortical regions were unaffected. Results support our hypothesis of preserved nAChRs in 
temporal cortex in VaD and are consistent with an autopsy study which used the α4β2 
affinity nicotinic ligand 3H-epibatidine to demonstrate temporal preservation in VaD 
relative to controls (Martin-Ruiz et al., 2000). Deficits in thalamus and right caudate were 
more unexpected, although the thalamus has been shown to be associated with a strong 
age-related decline in nAChR availability (32%, 4.8% decade-1) (Mitsis et al., 2008). 
Interestingly, Pimlott et al, observed an 11% reduction in 125I-5IA-85380 binding in 
tissue of the anteroprincipal nucleus of the thalamus, a region of the dorsal thalamus, in 
VaD compared to controls, but this was not statistically significant (Pimlott et al., 2004): 
small sample size reduced statistical power in that study (controls n=6, VaD n=3).  
 
Depletion of various nAChR subtypes in thalamus has been reported in AD and DLB at 
autopsy. 125I-α-bungarotoxin, a ligand used to visualise α7 nAChRs, was shown to be 
reduced in reticular nucleus in AD and DLB (Court et al., 2001; Court et al., 1999). 
Using 3H-nicotine, uptake was found to be lower in the lateral dorsal nucleus in DLB 
(Court et al., 1999), while for AD, there was an overall trend for decrease in most 
thalamic nuclei (Court et al., 2001). Decline of α6/α3 nAChRs in DLB has also been 
demonstrated in thalamus using 125I-α-conotoxinMII (Ray et al., 2004), but  previous 123I-
5IA-85380 investigations by the present authors did not reveal any significant alterations 
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in AD or DLB antemortem in thalamic binding. The discrepancy was most likely due to 
the study of different nAChR subtypes. Similarly, neuropathological and imaging studies 
have revealed deficits in nAChRs in striatum (caudate) in AD (O'Brien et al., 2007; 
Pimlott et al., 2004; Rinne et al., 1991) and to an even greater extent in DLB (O'Brien et 
al., 2008; Pimlott et al., 2004; Ray et al., 2004). Nicotinic cholinergic deficits in thalamus 
and striatum are associated with all three main subtypes of late life dementia, possibly 
suggesting an important role in common cognitive impairments involving these 
structures, such as attention, executive function or memory dysfunctions. Further studies 
of cholinergic changes in these regions, combined with detailed neuropsychology will be 
required to investigate this further. 
 
A significant increase in normalised 123I-5IA-85380 uptake was discovered in the 
bilateral cuneus and right middle occipital gyrus in VaD relative to controls. This result 
was unexpected, and since there were no similar patterns in rCBF found within this or 
surrounding regions, tracer kinetic factors are an unlikely explanation. Elevated scaled 
123I-5IA-85380 binding in cuneus has previously been demonstrated in DLB and was 
associated with visual hallucinations (O'Brien et al., 2008). Visual hallucinations have 
also been associated with VaD, but as only 14% (2/14) of the VaD subjects in this study 
had a recent history of visual hallucinations we could not analyse this further. Diffusion 
imaging has shown a rich neural connectivity between thalamus and cortex in human 
brain in vivo (Behrens et al., 2003; Johansen-Berg et al., 2005), in particular, using a 
probabilistic tractography method to create a ‘thalamic connectivity atlas 
(http://www.fmrib.ox.ac.uk/connect/)’, which calculates the probability of anatomical 
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neural connectivity between a specific thalamic coordinate and cortex (Johansen-Berg et 
al., 2005). Using the atlas, peak loss of nicotinic binding in thalamus in VaD, i.e., 8 -12 
20, demonstrated highest probabilities of connectivity in temporal and occipital cortices. 
Therefore as an exploratory exercise, the relationship between thalamic and cuneal 
normalised 123I-5IA-85380 uptake was investigated in an attempt to understand cuneal 
upregulation in VaD and its possible association with uptake in thalamus. A negative 
trend (p=0.06) was observed between thalamic and cuneal cluster 123I-5IA-85380 binding 
in VaD, which could suggest that the increase in relative 123I-5IA-85380 uptake in cuneus 
could be a compensatory response to reduced cholinergic activity in dorsal thalamus, 
though this remains speculative.  
 
Relative 123I-5IA-85380 uptake in VaD showed a pattern distinct from rCBF. Significant 
hypoperfusion was observed in anterior cingulate in VaD compared to controls. This was 
broadly in agreement with previous rCBF investigations of subcortical VaD where 
deficits in anterior cingulate are a prominent feature (Hanyu et al., 2004; Shim et al., 
2006; Yang et al., 2002). Other regions shown to be affected are frontal (Hanyu et al., 
2004; Yoshikawa et al., 2003), thalamus, striatal and temporal lobes (Shim et al., 2006; 
Yang et al., 2002). Generally blood flow abnormalities in VaD are largely anterior. PET 
studies have also revealed metabolic reductions in frontal and anterior cingulate (Nagata 
et al., 2000; Sultzer et al., 1995). Deviation between these studies and present results are 
probably due to variance of VaD populations and differences in analysis methods, e.g., 
the use of image masking to avoid infarcts in areas of temporal and frontal lobes. As a 
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matter of interest, when SPM height thresholds were lowered from Puncorrected ≤ 0.001 to 
Puncorrected ≤ 0.01, rCBF loss extended to frontal regions.   
 
There was no concordance between cognitive variables in VaD with relative 123I-5IA-
85380 uptake. The lack of correlates with 123I-5IA-85380 uptake has also been 
demonstrated in previous studies with AD and DLB and also with non-demented PD 
subjects (Fujita et al., 2006; O'Brien et al., 2007, 2008). Results may have been due to the 
small sample size, rudimentary nature of the cognitive measures, significant α4β2 
receptor loss occurring early before symptoms, or lack of sensitivity of nicotinic SPECT 
data to cognitive changes.  
 
Limitations of the present study included small sample size and in analysis methodology 
of which has been explained in a previous report, i.e., scaling the imaging data to mean 
global brain activity (O'Brien et al., 2008). The current method does not give an absolute 
quantitative measure of α4β2 nAChRs and cannot detect global changes. Absolute 
quantification of nAChRs requires either information via plasma tracer measurements or 
selection of a suitable reference region without nAChRs. Blood sampling was not 
practical for our VaD population, and no brain area devoid of nAChRs has been 
described. In addition, an age related decline in nicotinic 123I-5IA-85380 SPECT binding 
has been demonstrated (Mitsis et al. 2008), and due to lack of evidence, the effect of 
gender on 123I-5IA-85380 uptake is unclear. In our study both age and gender were (i) 
balanced across groups and (ii) did not significantly correlate with the imaging data. 
Hence for the main analyses, we did not control for these variables.  
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In conclusion, this was the first study to examine the distribution of relative in 123I-5IA-
85380 uptake in vivo in VaD using SPM2. The measurement of 123I-5IA-85380 may be 
affected by differences in rCBF between groups but the results indicated that such 
possibilities are small. Compared to controls, significant reductions in normalised 123I-
5IA-85380 uptake were confined to sub-cortical regions (principally dorsal thalamus) in 
VaD, whereas in cortical regions in accordance with previous studies, uptake was 
preserved. Unexpectedly, significant elevation of normalised 123I-5IA-85380 uptake was 
observed in cuneus in VaD relative to controls and could be a compensatory response to 
reduced cholinergic activity in dorsal thalamus. The 123I-5IA-85380 results in VaD are 
merely suggestive and therefore require further independent verification. 
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Table 1  
Demographic and neuropsychological data of subjects studied with 123I-5IA-85380 and 
99mTc-exametazime SPECT. 
 
 
 
Control 
 
VaD 
 
p value 
    
n 16 14  
Sex (M: F) 10: 6 10: 4 Ns 
Age 75.4 ± 4.5 77.7 ± 5.5 Ns 
MMSE (max 30) 28.8 ± 1.1 20.7 ± 5.2 <0.001 
CAMCOG (max 107) 97.9 ± 3.8 69.9 ± 19.9 <0.001 
CAMCOGmemory (max 27) 24.0 ± 1.8 15.9 ± 6.4 <0.001 
Executive Function (max 28) 23.3 ± 3.1 12.8 ± 5.7 <0.001 
Fluctuation (max 16) 0 3.2 ± 4.3 Na 
    
NPItotal (max 144) 0 10.4 ± 9.6 Na 
NPI Hallucinations (Yes: No) 0: 16 2: 12 Na 
NPI Delusions (Yes: No) 0: 16 1: 13 Na 
NPI Depression (Yes: No) 0: 16 2: 12 Na 
    
 
Values expressed as (Mean ± 1 Standard deviation) 
VaD = Vascular Dementia; MMSE = Mini-Mental State Examination; CAMCOG = Cambridge Cognitive 
Examination; NPI = Neuropsychiatric Inventory; Ns = Not significant; Na = Not applicable. 
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Table 2  
Location and peak significance of 123I-5IA-85380 comparisons. For each peak, table 
shows cluster-level significance (Pcorrected), spatial extent (k), t and Z scores and peak 
MNI coordinates together with their location and corresponding nearest Brodmann areas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cluster-level 
(Pcorrected) 
Extent 
(k) 
t, Z MNI Coordinates 
(x,y,z) (mm) 
Anatomical Region Brodmann 
Area 
 
     
A (Controls > VaD)   
     
0.002 190 5.2, 4.3 8, -12, 20 Right thalamus, anterior nucleus  
  4.9, 4.2 4, -8, 16 Right thalamus  
  4.8, 4.1 -24, -24, 20 Left cerebrum, white matter  
  3.6, 3.2 16, 20, 12 Right caudate  
      
     
B (VaD > Controls)  
     
0.011 127 5.2, 4.3 0, -84, 16 Left occipital lobe, cuneus 18 
  4.7, 4.0 12, -76, 32 Right occipital lobe, cuneus 7 
  4.1, 3.6 12, -92, 8 Right middle occipital gyrus 18 
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Table 3  
Location and peak significance of 99mTc-exametazime comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cluster-level 
(Pcorrected) 
Extent 
(k) 
t, Z MNI Coordinates 
(x,y,z) (mm) 
Anatomical Region Brodmann 
Area 
 
     
A (Controls > VaD)   
     
0.001 144 4.5, 3.8 -12, 20, 24 Left anterior cingulate 32 
  4.4, 3.8 4, 28, 16 Right anterior cingulate 24 
  3.9, 3.5 16, 0, 40 Right cingulate gyrus 24 
      
     
B (VaD > Controls)  
No suprathreshold or significant clusters 
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Fig. 1. Examples of lesion masking. (A) Transverse 99mTc-exametazime (perfusion) scans 
showing a focal infarct of the left pre and post central gyrus (VaD 1), the other (VaD 2) 
with widespread cortical infarcts in gyri of the right hemisphere (middle temporal, 
superior temporal and inferior frontal) and left hemisphere (middle occipital and middle 
temporal). (B) 99mTc-exametazime scans with mask (green). (C) Associated 123I-5IA-
85380 (nicotinic) scans. 
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Fig. 2. SPM results (Puncorrected ≤ 0.001, k ≥ 16 voxels) presented on a “glass brain” in the 
sagittal, coronal and transverse views. (A) Significant reduction of 123I-5IA-85380 uptake 
in 14 VaD patients relative to 16 controls. (B) Significant increase in VaD compared to 
controls. (C) Results from (A) projected onto the 99mTc-exametazime SPECT template 
(blue regions) together with results from (B) (orange regions). Images presented in the 
neurological convention, i.e. subjects left are on left side. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  28
Fig. 3. SPM results (Puncorrected ≤ 0.001, k ≥ 16 voxels) presented on a “glass brain” in the 
sagittal, coronal and transverse views. (A) Significant loss of 99mTc-exametazime uptake 
in VaD relative to controls. (B) Results from (A) projected onto the 99mTc-exametazime 
SPECT template (yellow region). Images presented in the neurological convention. 
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Fig. 4. Representative transverse 123I-5IA-85380 and 99mTc-exametazime SPECT scans in 
standard MNI space of an individual control and VaD patient (matched for age and 
gender). Note the thalamic decline (white arrows) and cuneal increase (green arrows) in 
123I-5IA-85380 binding in VaD relative to the control.  
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Fig. 5. Relationship between 123I-5IA-85380 normalised uptake values in thalamus and in 
cuneal clusters in VaD subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
